CBD Research Studies And Authorities 2018-07-16T08:21:18+00:00

Research Studies By Indication/Ailment (Click Any Panel)

Each panel below will forward you to a page with a list of published scientific studies relating to the endocannabinoid system (ECS) and/or substances that interact with the ECS, such as phyto-cannabinoids. These lists are not meant to be exhaustive, they are provided as a reference tool only to show indications where there is pre-clinical or clinical evidence that supports further investigation. CB1 Capital assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.

Studies of the ECS are instructive because they can provide a better sense of what indications may show efficacy through treatment targeted at the ECS and/or certain substrates that interact with the ECS. One such example is AEA and THC. AEA is a chemical that is produced in the human body that shares similar characteristics with THC that is derived from the cannabis plant. Studies have found that AEA is analogous in action to THC, so we can review studies of AEA for guidance on what indications might benefit from supplemental THC treatment. AEA is the endocannabinoid that produces the feeling commonly referred to as the “runner’s high.”

Liver
Chronic Pain
Motor Disorders
Skin Conditions
Epilepsy
cancer pain
neuropathic pain
alzheimers
addiction
obesity-metabolic syndrome
neuropsychiatric disorders
fibrosis
Pregnancy Related
huntingtons disease
ptsd
migraines
anxiety
glaucoma
atherosclerosis
fybromyalgia
crohn's ibd
adhd
schizophrenia
depression
neo-natal hypoxia
parkinsons disease
osteoporosis
cbd muscular dystrophy
cbd glioma brain tumors
type two diabetes
autism